178 related articles for article (PubMed ID: 10491010)
1. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
2. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
3. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
5. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
8. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
9. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.
Woodberry T; Gardner J; Mateo L; Eisen D; Medveczky J; Ramshaw IA; Thomson SA; Ffrench RA; Elliott SL; Firat H; Lemonnier FA; Suhrbier A
J Virol; 1999 Jul; 73(7):5320-5. PubMed ID: 10364278
[TBL] [Abstract][Full Text] [Related]
14. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A
J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910
[TBL] [Abstract][Full Text] [Related]
15. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
Slingluff CL; Cox AL; Henderson RA; Hunt DF; Engelhard VH
J Immunol; 1993 Apr; 150(7):2955-63. PubMed ID: 7681084
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
17. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
Takahashi T; Irie RF; Morton DL; Hoon DS
Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
[TBL] [Abstract][Full Text] [Related]
18. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
19. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
20. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
Chen Q; Jackson H; Cebon J; Gibbs P; Davis ID; Trapani JA
Melanoma Res; 2000 Feb; 10(1):16-25. PubMed ID: 10711636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]